The Patent Trial and Appeal Board on Thursday upheld the validity of an Alcon patent covering the glaucoma treatment Travatan Z, rejecting arguments by generics maker Argentum that the invention was obvious.
Fifteen law firms will guide initial public offerings from 13 companies that are expected to raise more than $1.1 billion during the week of Sept. 24, a busy lineup dominated by technology and life sciences firms going public during a sweet spot on the annual IPO calendar.
Compounder Athenex Pharma Solutions LLC is wrongly attempting to broaden a U.S. Food and Drug Administration policy governing bulk compounding, and its “gross misinterpretation” must be kept out of Par Pharmaceutical’s suit challenging that policy, an AmerisourceBergen Corp. subsidiary has told a D.C. federal court.
DLA Piper has brought in life sciences attorneys from Hogan Lovells and Vinson & Elkins LLP, Baker Donelson Bearman Caldwell & Berkowitz PC has boosted its health care group in Memphis, Tennessee, Aquestive Therapeutic has nabbed the head of Day Pitney LLP's life sciences group and Clearside Biomedical has hired an in-house veteran to lead its legal team.
Alleging that the Third Circuit contradicted its own prior rulings and created a split with the Ninth Circuit by dismissing a Johnson & Johnson consumer’s proposed class action over talcum powder as “buyer’s remorse,” the customer’s attorneys on Friday asked for the full court to rehear the case.
Allergan PLC and the Saint Regis Mohawk Tribe slapped generic drug manufacturer Amneal Pharmaceuticals with a patent infringement suit over the dry-eye drug Restasis in Delaware federal court on Thursday, even as the fate of related patents for the drug hangs in the balance at the Federal Circuit.
A Texas federal judge has declined to throw out a suit by a medical device developer accusing a California attorney of scamming it out of $1.76 million, ruling that the court did have jurisdiction over the case.
A Delaware vice chancellor on Thursday let stand a series of stock conversions that biotech company MabVax Therapeutics Holdings Inc. had worried were in question due to claims of a “well-planned” and “extensive” pump-and-dump scheme that is the subject of a recent federal lawsuit.
Residents of a Chicago suburb have slapped Sterigenics International Inc. and its private equity owner with a proposed class action in Illinois circuit court that claims the sterilization company has for decades knowingly emitted a highly carcinogenic chemical from a local facility without disclosing the risks.
A California federal judge has awarded $35 million in attorneys' fees as part of a settlement for end-payors that claimed a group of pharmaceutical companies delayed the release of a generic form of the Lidoderm pain patch.
The Office of the U.S. Solicitor General has urged the U.S. Supreme Court to overturn a Third Circuit decision reviving multidistrict litigation over Merck Sharp & Dohme Corp.’s alleged failure to warn about a risk of femoral fractures from its osteoporosis drug Fosamax, saying such claims are preempted because regulators rejected the company's proposed warning.
A California federal judge has agreed to send back to state court a wage-and-hour suit brought by a group of former Johnson & Johnson Consumer Inc. workers, finding that the amount of money in controversy fell short of the threshold necessary for the federal court to hear the case.
Attorneys for “opioid babies” whose mothers used prescription narcotics argued on Thursday for new multidistrict litigation focused on the infants, citing “grave concerns” that an existing MDL over the opioid crisis is woefully deficient.
An Ohio federal judge ordered Cavitch Familo & Durkin Co. and three of its attorneys to pay more than $655,000 in sanctions Wednesday for its discovery abuses while representing Healthcare Essentials Inc., which was ordered to pay medical device maker KCI USA Inc. $645 million in trebled damages earlier this month for stealing and rebranding KCI’s product.
A Massachusetts federal magistrate judge has told Anderson & Wanca and Swartz & Swartz PC that they failed to submit sufficient evidence of the firms' expenses that went into striking a $4.75 million deal with Vertex Pharmaceuticals Inc. to end class action allegations of unsolicited faxes.
The Seventh Circuit on Thursday refused to reconsider its decision to overturn a $3 million verdict blaming GlaxoSmithKline for the suicide of a Reed Smith partner who had been taking a generic version of its Paxil drug.
The Federal Trade Commission told a company selling intravenous therapy products to cease marketing its iV Cocktails as alternative treatments for serious diseases without backing those claims with scientific and medical testing, according to a consent order filed Thursday.
A Houston doctor and the owner of the pain management clinic where she worked were each sentenced to 35 years in prison by a federal judge in Texas on Thursday for their roles in running what prosecutors called the “most prolific hydrocodone pill mill in Houston.”
A California federal judge has rebuffed Johnson & Johnson's bid to dismiss a suit alleging it violates state warning label and false advertising laws by selling asbestos-contaminated talcum powder products, writing the consumer products giant was "simply demanding more" detail than is necessary in a complaint.
A New Hampshire court has given the state the go-ahead to pursue its claims that Purdue Pharma pushed the opioid OxyContin with a deceptive marketing campaign that overstated the drug’s benefits and underplayed its risks.
While in-house technology investments on the scale and complexity needed to compete with large firms remain cost prohibitive for small and midsize law firms, cloud-based services offer significant cost savings and productivity gains with little to no capital investment, says Holly Urban of Effortless Legal LLC.
CVS is the first major drugstore company to offer customers the option to use their smartphone to “see” a doctor. With the U.S. Department of Justice affording more resources to health care fraud prosecutions, telemedicine services are certain to attract the scrutiny of investigators, say Lionel André and Michelle Bradford of Murphy & McGonigle PC.
With the Milbank/Cravath pay scale once again equalizing compensation at many Am Law 100 firms, there is even more pressure for firms to differentiate themselves to top lateral associate candidates. This presents strategic considerations for both law firms and lateral candidates throughout the recruitment process, says Darin Morgan of Major Lindsey & Africa.
In a ruling earlier this month concerning Bayer's "One A Day" vitamin gummies, a California state appeals court clarified how the defendant cannot rely on the fine print to escape a mislabeling claim at the pleadings stage. In doing so, the court appears to have laid a road map for how to defeat class certification in such cases, say Robert Guite and Jay Ramsey of Sheppard Mullin Richter & Hampton LLP.
In this series featuring law school luminaries, Stanford Law School professor Jeffrey Fisher discusses his motivation for teaching, arguing before the U.S. Supreme Court and what the court might look like if Judge Brett Kavanaugh is confirmed.
A recently published research paper concludes that a significant proportion of patients with malignant mesotheliomas carry inherited mutations in cancer-associated genes. Well-informed lawyers on both sides of the aisle can effectively use such data to materially alter the outcome of cases, say Kirk Hartley and David Schwartz of ToxicoGenomica.
The Federal Circuit's decision in the gene editing technology battle between the University of California and the Broad Institute provides that the two parties' patents can coexist. Biotech companies using this technology should seek licenses from both UC and the Broad Institute, say attorneys at Faegre Baker Daniels LLP.
The Ninth Circuit's decision last month in Khoja v. Orexigen Therapeutics — placing constraints on the record a court may consider in deciding falsity and scienter under the securities laws — countermands the U.S. Supreme Court’s direction to courts in Omnicare and Tellabs, say attorneys with BakerHostetler.
A recent study suggests that triclosan, a common antibacterial agent, can promote colonic inflammation and cancer in mice when ingested at what the authors deem normal human exposure levels from using certain consumer products. But this research is unlikely to find its way into the courtroom, say Douglas Pfeifer and Richard Morgan of Bowman and Brooke LLP and Brent Kerger of Exponent Inc.
The first comprehensive overhaul of California's Rules of Professional Conduct in nearly 30 years becomes operational on Nov. 1. Some of the new rules mirror the model language used by the American Bar Association, but many continue to reflect California’s unique approach to certain ethical questions, says Mark Loeterman of Signature Resolution LLC.